<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058367</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/023314</org_study_id>
    <nct_id>NCT03058367</nct_id>
  </id_info>
  <brief_title>Benefit and Tolerability of IQP-AE-103 in Weight Loss</brief_title>
  <official_title>Double-blind, Randomised, Three-armed, Placebo-controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg
      and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in body weight (kg)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference in mean change of body weight (kg) between the higher dosed verum (1980 mg a day) and placebo group after 12 weeks of intervention in comparison to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight (kg)</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in body weight (kg) after 2, 4, 8, and 12 weeks of intervention, each in comparison to baseline, between the two active and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight (%)</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in body weight (%) after 2, 4, 8, and 12 weeks of intervention, each in comparison to baseline, between the two active and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject weight loss</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Proportion of subjects who lost at least 3% and 5% of baseline body weight after 2, 4, 8, and 12 weeks intervention, each in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference (cm)</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in waist circumference after 2, 4, 8, and 12 weeks intervention, each in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hip circumference (cm)</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in hip circumference after 2, 4, 8, and 12 weeks intervention, each in comparison to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety parameters (lab parameters, vital signs)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in safety lab parameters, vital signs</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>High dose IQP-AE-103 (1980mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose IQP-AE-103 (990mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AE-103 (330mg)</intervention_name>
    <description>High dose capsules</description>
    <arm_group_label>High dose IQP-AE-103 (1980mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AE-103 (165mg)</intervention_name>
    <description>Low dose capsules</description>
    <arm_group_label>Low dose IQP-AE-103 (990mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical to verum capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65 years

          2. Overweight to moderately obese subjects (BMI ≥ 25 and &lt; 35 kg/m2)

          3. Expressed desire for weight loss

          4. Accustomed to 3 main meals/day

          5. Commitment to take IP as recommended

          6. Commitment to adhere to diet recommendation during the study

          7. Commitment to maintain habitual level of activity/exercise during the study

          8. Consistent and stable body weight for 3 months prior to V1

          9. Commitment to avoid the use of other weight management products or programs during
             study

         10. Commitment and ability to complete the subject diary and study questionnaires

         11. Females of childbearing potential: negative pregnancy testing (beta HCG-test in urine)
             at V1, agreement to use appropriate contraception methods during the study period

         12. Consents to participate, understands requirements of the study and is willing to
             comply

        Exclusion Criteria:

          1. Known sensitivity to the ingredients of the investigational product or source of
             ingredients

          2. Pregnancy or nursing

          3. Smoking cessation within 6 months prior to V1 or during the study (regular smoking
             during the study at the same level as prior to the study is allowed)

          4. Current or history of abuse of drugs, alcohol or medication

          5. Clinically relevant excursions of safety laboratory parameter

          6. Diabetes mellitus type 1

          7. Untreated or unstable diabetes mellitus type 2

          8. Untreated or unstable endocrine disorders which may influence body weight (e.g.
             Cushing's disease, thyroid gland disorders)

          9. Stenosis in the gastrointestinal (GI) tract

         10. Bariatric surgery in subject´s medical history

         11. Abdominal surgery within the last 6 months prior to V1

         12. Current use of medications that may affect body weight (eg. antipsychotics,
             anti-depressants, corticosteroids etc.)

         13. Presence of acute or chronic gastrointestinal disease (e.g. inflammatory bowel
             disease, coeliac disease, pancreatitis)

         14. Digestion/absorption disorders in gastrointestinal (GI) tract

         15. History of eating disorders such as bulimia, anorexia nervosa within the past 12
             months prior to V1

         16. Other serious organ or systemic diseases such as cancer within the last 5 years prior
             to V1

         17. Any electronic medical implant

         18. Use of any medication that could influence GI functions such as antibiotics within 4
             weeks and any laxatives, opioids, glucocorticoids, anticholinergics within last 3
             months prior to V1 and during the study, as per investigator judgement

         19. Any medication or use of products for the treatment of obesity (e.g. orlistat, other
             fat binder, carbohydrate/starch blocker, fat burner, satiety products etc.) within
             last 3 months prior to V1 and during the study

         20. Participation in similar studies or weight loss programs within last 4 weeks prior to
             V1

         21. Participation in other studies during the last 4 weeks prior to V1

         22. Inability to comply

         23. Presence of other factor(s) or medication that should preclude subject participation
             as per investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analyze &amp; Realize</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

